MD Anderson Participates in Studying Alternative Treatment Methods for Cancer

Although recent advancements in medicine have made strides in treating cancer, it is still the second leading cause of death within our country. Currently, there are approximately 13 million people in America who either have had or currently have cancer. Over 500,000 people are expected to die this year (over 1,500 per day) in the US from some form of the disease. That’s why the MD Anderson Cancer Center, along with many other cancer research facilities across the world are steadily researching new treatments and searching for a cure.

http://bionews-tx.com/news/2013/05/14/md-anderson-participates-in-studying-alternative-treatment-methods-for-cancer/

Baylor Researcher Receives Grant to Study Immunotherapy Treatment for Osteosarcoma

read about a Baylor Researcher Received a Grant to Study Immunotherapy Treatment for Osteosarcoma.

http://bionews-tx.com/news/2013/05/06/baylor-researcher-receives-grant-to-study-immunotherapy-treatment-for-osteosarcoma/

MD Anderson Oncologist questions cancer treatment using radioactive bacteria

A risky new cancer treatment has many scientists raising an eyebrow, including Dr. James Abbruzzese of the University of Texas MD Anderson Cancer Center in Houston. The treatment involves using irradiated bacteria to attack tumors.

http://bionews-tx.com/news/2013/04/23/md-anderson-oncologist-questions-cancer-treatment-using-radioactive-bacteria/

New potential cancer treatment found by UT Southwestern

Cancer researchers at the University of Texas Southwestern Medical Center have found that they may be able to limit the uncontrolled replication of certain types of cancer through a method known as alternative splicing which limits the enzyme telomerase.

http://bionews-tx.com/news/2013/04/20/new-potential-cancer-treatment-found-by-ut-southwestern/

Bio-Path Holdings Expands Reach of Non-Toxic, MD Anderson-Tested Cancer Treatment

Read about how Bio-Path Holdings Expands Reach of Non-Toxic, MD Anderson-Tested Cancer Treatment.

http://bionews-tx.com/news/2013/04/04/bio-path-holdings-expands-reach-of-non-toxic-md-anderson-tested-cancer-treatment/

Findings Presented At San Antonio Breast Cancer Symposium Reveal Benefits of Tamoxifen In Breast Cancer Treatment

Read about how Findings Presented At San Antonio Breast Cancer Symposium Reveal Benefits of Tamoxifen In Breast Cancer Treatment.

http://bionews-tx.com/news/2013/03/20/findings-presented-at-san-antonio-breast-cancer-symposium-reveal-benefits-of-tamoxifen-in-breast-cancer-treatment/

Methodist University Researchers Leaders In New TB Treatment Development

Methodist University Researchers Leaders In New TB Treatment Development

http://bionews-tx.com/news/2013/03/19/methodist-university-researchers-leaders-in-new-tb-treatment-development/

UT Health Center Considers Joint Initiative With Tyler Junior College To Offer ER Dental Treatment

Read about how the UT Health Center Considers a Joint Initiative With Tyler Junior College To Offer ER Dental Treatment.

http://bionews-tx.com/news/tjc-ut-health-center-mull-dental-partnership/

Melatonin No Help For Late-stage Cancer Weight Loss U. OF Texas Study Finds

Reuters’ Kathryn Doyle reports that notwithstanding encouraging results in the past, a new clinical trial published in the Journal of Clinical Oncology has determined that orally administered Melatonin has proved ineffective in helping advanced cancer patients improve appetites or achieve weight loss.

http://bionews-tx.com/news/melatonin-no-help-for-late-stage-cancer-weight-loss-us-study/

Celltex Therapeutics Begins Cooperation With FDA to Resume Stem Cell Treatments

Texas-based adult stem cell treatment provider Celltex is apparently making strides in winning approval from the FDA, according to a recent wide-ranging article from Nature.com that outlines the controversial past and present of adult stem cell research and treatment. As a result of close scrutiny from the FDA in 2012 over what the organization deemed to be unproven treatment methods using adult stem cells, Celltex was forced to capitulate. After failing to argue effectively that stem cell treatments are in essence “tissue transplants” and not traditional drug treatments, thus not requiring the same rigorous clinical trials, the company was forced to move its treatment facilities to Mexico in order to continue to offer its patients ongoing stem cell treatment.

http://www.swbiosearch.com/2013/02/18/celltex-therapeutics-begins-cooperation-with-fda-toresume-stem-cell-treatments/